Biosimilar Insulin Access Act of 2020

Bill: 116-hr-8190
Sponsor: full_name: Rep. Grothman, Glenn [R-WI-6]
Introduced: 2020-09-08
Policy area: Health
Subjects: Blood and blood diseases

Competition and antitrust

Drug safety, medical device, and laboratory regulation

Drug therapy

Health technology, devices, supplies

Intellectual property

Licensing and registrations

Prescription drugs
Latest action: action_date: 2020-09-16
text: Sponsor introductory remarks on measure. (CR H4487)

Summaries:
action_date: 2020-09-08
action_desc: Introduced in House
text: <p><b>Biosimilar Insulin Access Act of 2020</b></p> <p>This bill establishes that, if the Food and Drug Administration (FDA) finds that an insulin is biosimilar to a reference product, the insulin shall be deemed interchangeable with the reference product. (A biological product is biosimilar to a reference product if the two products are highly similar and have no clinically meaningful differences; the reference product generally receives FDA approval first, but the biosimilar product is typically less expensive.)</p> <p>Under current law, a biological product that is biosimilar to a reference product may be deemed interchangeable with the reference product only if it meets additional requirements. Current law provides that interchangeable products may be substituted for each other without the prescriber's involvement.</p>

tv_txt: I 116th CONGRESS 2d Session H. R. 8190 IN THE HOUSE OF REPRESENTATIVES September 8, 2020 Mr. Grothman introduced the following bill; which was referred to the Committee on Energy and Commerce A BILL To amend the Public Health Service Act to deem any insulin that is determined by the Secretary to be biosimilar to the reference product to be interchangeable with the reference product, and for other purposes.

1. Short title This Act may be cited as the Biosimilar Insulin Access Act of 2020 . 2. Deeming biosimilar insulin to be interchangeable (a) In general Section 351(k)(3) of the Public Health Service Act ( 42 U.S.C. 262(k)(3) ) is amended by adding at the end the following: (B) Biosimilar insulin (i) Deemed interchangeable Notwithstanding paragraph (4), an insulin is deemed to be interchangeable with the reference product if the insulin is determined by the Secretary to be biosimilar to the reference product. (ii) Shortening exclusivity for first interchangeable product (I) Action instituted If an action is instituted under subsection (l)(6) against the applicant that submitted the application for an insulin that is the first approved interchangeable biosimilar biological product, paragraph (6) shall apply with respect to such insulin without regard to paragraph (6)(A). (II) Action not instituted If such an action is not instituted with respect to an insulin that is approved as an interchangeable biosimilar biological product, the Secretary shall make a determination on the interchangeability of any second or subsequent biological product without regard to the delay otherwise required by paragraph (6). (iii) Applicability Clause (i) applies without regard to whether the insulin is determined to be biosimilar to the reference product, or deemed to be licensed pursuant to this section, before or after the date of enactment of the Biosimilar Insulin Access Act of 2020 . . (b) Conforming changes Section 351(k)(3) of the Public Health Service Act ( 42 U.S.C. 262(k)(3) ) is amended— (1) by striking Upon review and inserting the following: (A) In general Upon review ; (2) by striking (A) the Secretary and inserting the following: (i) the Secretary ; (3) by striking (i) is biosimilar and inserting the following: (I) is biosimilar ; (4) by striking (ii) can be and inserting the following: (II) can be ; and (5) by striking (B) the applicant and inserting the following: (ii) the applicant .